Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload

被引:17
|
作者
Li, Wei-ming [1 ]
Zhao, Yi-fan [1 ]
Zhu, Guo-fu [1 ]
Peng, Wen-hui [1 ]
Zhu, Meng-yun [1 ]
Yu, Xue-jing [1 ]
Chen, Wei [1 ]
Xu, Da-chun [1 ]
Xu, Ya-wei [1 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Cardiol, Sch Med, Shanghai 200072, Peoples R China
基金
中国国家自然科学基金;
关键词
cardiac hypertrophy; dual specific phosphatase 12; c-Jun N-terminal kinase (JNK); signalling pathway; SP600125; N-TERMINAL KINASE; HEART-FAILURE; ACTIVATION; REGULATORS; CARDIOMYOPATHY; IDENTIFICATION; APOPTOSIS; REVEALS; BINDING; ERK1/2;
D O I
10.1042/CS20160664
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual specific phosphatase (DUSP) family, which is characterized by its DUSP activity to dephosphorylate both tyrosine and serine/threonine residues on one substrate. Some DUSPs have been identified as being involved in the regulation of cardiac hypertrophy. However, the role of DUSP12 during pathological cardiac hypertrophy is still unclear. In the present study, we observed a significant decrease in DUSP12 expression in hypertrophic hearts and cardiomyocytes. Using a genetic loss-of-function murine model, we demonstrated that DUSP12 deficiency apparently aggravated pressure overload-induced cardiac hypertrophy and fibrosis as well as impaired cardiac function, whereas cardiac-specific overexpression of DUPS12 was capable of reversing this hypertrophic and fibrotic phenotype and improving contractile function. Furthermore, we demonstrated that JNK1/2 activity but neither ERK1/2 nor p38 activity was increased in the DUSP12 deficient group and decreased in the DUSP12 overexpression group both in vitro and in vivo under hypertrophic stress conditions. Pharmacological inhibition of JNK1/2 activity (SP600125) is capable of reversing the hypertrophic phenotype in DUSP12 knockout (KO) mice. DUSP12 protects against pathological cardiac hypertrophy and related pathologies. This regulatory role of DUSP12 is primarily through c-Jun N-terminal kinase (JNK) inhibition. DUSP12 could be a promising therapeutic target of pathological cardiac hypertrophy. DUSP12 is down-regulated in hypertrophic hearts. An absence of DUSP12 aggravated cardiac hypertrophy, whereas cardiomyocyte-specific DUSP12 overexpression can alleviate this hypertrophic phenotype with improved cardiac function. Further study demonstrated that DUSP12 inhibited JNK activity to attenuate pathological cardiac hypertrophy.
引用
收藏
页码:141 / 154
页数:14
相关论文
共 50 条
  • [21] Cinnamaldehyde attenuates pressure overload-induced cardiac hypertrophy
    Yang, Liu
    Wu, Qing-Qing
    Liu, Yuan
    Hu, Zhe-Fu
    Bian, Zhou-Yan
    Tang, Qi-Zhu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 14345 - 14354
  • [22] Direct monitoring pressure overload predicts cardiac hypertrophy in mice
    Duan, Sheng Zhong
    Ivashchenko, Christine Y.
    Whitesall, Steven E.
    D'Alecy, Louis G.
    Mortensen, Richard M.
    PHYSIOLOGICAL MEASUREMENT, 2007, 28 (11) : 1329 - 1339
  • [23] Puerarin attenuates pressure overload-induced cardiac hypertrophy
    Yuan, Yuan
    Zong, Jing
    Zhou, Heng
    Bian, Zhou-Yan
    Deng, Wei
    Dai, Jia
    Gan, Hua-Wen
    Yang, Zheng
    Li, Hongliang
    Tang, Qi-Zhu
    JOURNAL OF CARDIOLOGY, 2014, 63 (1-2) : 73 - 81
  • [24] Evodiamine attenuates pressure overload-induced cardiac hypertrophy
    Li, Fangfang
    Yuan, Yuan
    Zhang, Ning
    Wu, Qingqing
    Li, Jin
    Zhou, Mengqiao
    Yang, Zheng
    Tang, Qizhu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (07): : 10202 - 10213
  • [25] Cardiac-Specific PID1 Overexpression Enhances Pressure Overload-Induced Cardiac Hypertrophy in Mice
    Liu, Yaoqiu
    Shen, Yahui
    Zhu, Jingai
    Liu, Ming
    Li, Xing
    Chen, Yumei
    Kong, Xiangqing
    Song, Guixian
    Qian, Lingmei
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2015, 35 (05) : 1975 - 1985
  • [26] Post-translational regulation of calsarcin-1 during pressure overload-induced cardiac hypertrophy
    Paulsson, Anna K.
    Franklin, Sarah
    Mitchell-Jordan, Scherise A.
    Ren, Shuxun
    Wang, Yibin
    Vondriska, Thomas M.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2010, 48 (06) : 1206 - 1214
  • [27] Analyzing gene expression profiles with preliminary validations in cardiac hypertrophy induced by pressure overload
    Gao, Jing
    Li, Yuhong
    Wang, Tongmei
    Shi, Zhuo
    Zhang, Yiqi
    Liu, Shuang
    Wen, Pushuai
    Ma, Chunyan
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2018, 96 (08) : 701 - 709
  • [28] Differential Effects of Myocardial Afadin on Pressure Overload-Induced Compensated Cardiac Hypertrophy
    Zankov, Dimitar P.
    Sato, Akira
    Shimizu, Akio
    Ogita, Hisakazu
    CIRCULATION JOURNAL, 2017, 81 (12) : 1862 - +
  • [29] The histone demethylase PHF8 represses cardiac hypertrophy upon pressure overload
    Liu, Xiaoqian
    Wang, Xuping
    Bi, Yanping
    Bu, Peili
    Zhang, Mingxiang
    EXPERIMENTAL CELL RESEARCH, 2015, 335 (01) : 123 - 134
  • [30] Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy
    Ramos-Kuri, Manuel
    Rapti, Kleopatra
    Mehel, Hind
    Zhang, Shihong
    Dhandapany, Perundurai S.
    Liang, Lifan
    Garcia-Carranca, Alejandro
    Bobe, Regis
    Fischmeister, Rodolphe
    Adnot, Serge
    Lebeche, Djamel
    Hajjar, Roger J.
    Lipskaia, Larissa
    Chemaly, Elie R.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2015, 1853 (11): : 2870 - 2884